Paul H.
- Country
- The Netherlands
- Department
- #2203: oncology
Research Overview
- A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
- Phase 3 Randomized Study of Belzutifan Plus Zanzalintinib Versus Belzutifan Plus Placebo in Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy
Data & Insights
Has run more than one trial at 159 of 313 partner sites.
Specializations
Prostate Cancer Research
This investigator specializes in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on innovative therapeutic combinations and novel treatment approaches.
- Hormonal Therapy Innovations
- Chemotherapy Combinations
- Immunotherapy Applications
The research encompasses both conventional and emerging therapeutic strategies for advanced prostate cancer management.
Renal Cell Carcinoma Studies
The investigator conducts research in advanced renal cell carcinoma (RCC) treatment, including studies of targeted therapies and immunological approaches.
- Post-Nephrectomy Treatment
- Targeted Molecular Therapies
- Combination Treatment Strategies
Special attention is given to papillary RCC and clear cell carcinoma therapeutic interventions.
Advanced Cancer Therapeutics
Research interests extend to novel therapeutic combinations and treatment modalities for urological cancers.
- Survival Outcome Studies
- Disease Progression Assessment
- Radiopharmaceutical Applications
The investigator evaluates innovative treatment approaches for patients with advanced urological malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.